@investseekers investseekers

Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY. · Analyst brief as of 2026-06-22.

investseekers is overwhelmingly focused on NVO, framing oral Wegovy, global launches, China filings, and prescription data as the key upside drivers versus LLY competition. The distinctive read is that real-world oral Wegovy traction and valuation may offset pricing, competition, and cyber headlines, while still flagging genuine cyber and execution risks. No CALL_DIRECTIONAL or POSITION_DISCLOSURE signals appear in the payload, so this is more news-and-thesis tracking than explicit trading.

No explicit adds, trims, exits, or position disclosures are present, and there are no CALL_DIRECTIONAL signals to classify as trades. The author’s coverage is consistently concentrated in NVO, with bullish oral Wegovy, prescription, launch, pipeline, and analyst-update items offset by recurring cyber and valuation-risk posts. Concentration is high: NVO represents the bulk of both constructive and negative signals, so the brief should be treated as a Novo-centric GLP-1 thesis tracker rather than a diversified healthcare read.

Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.